Karyopharm – SENTRY Phase 3 Myelofibrosis Readout Watch

Summary Karyopharm announced an investor conference call following the June 2, 2026 ASCO oral presentation of full Phase 3 SENTRY trial results evaluating selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis. What Happened Karyopharm will host a conference call featuring senior management and Phase 3 SENTRY…